Moskowitz M A, Cutrer F M
Stroke Research Laboratory, Massachusetts General Hospital, Boston.
Annu Rev Med. 1993;44:145-54. doi: 10.1146/annurev.me.44.020193.001045.
Sumatriptan, recently introduced for the treatment of migraine, heralds the beginning of a molecular era in the pharmacological treatment of migraine headache. An indole (non-ergot alkaloid) derivative with agonist properties at a receptor resembling the 5-HT1D subtype (so-called 5-HT1-like receptor), sumatriptan is the first antimigraine medication to exhibit receptor-selective properties. Clinical data indicate that sumatriptan relieves headache, nausea, and photophobia in a majority of acute migraine patients, and it possesses favorable side effect and safety profiles. Of great importance, sumatriptan acts through a novel mechanism that we now know is shared by dihydroergotamine and other useful compounds for the treatment of acute migraine headaches. In this summary, we briefly review the drug's mechanism of action and the emerging clinical experience with its use.
舒马曲坦最近被用于治疗偏头痛，它标志着偏头痛药物治疗分子时代的开端。舒马曲坦是一种吲哚（非麦角生物碱）衍生物，对一种类似于5-HT1D亚型的受体（所谓的5-HT1样受体）具有激动剂特性，是首个表现出受体选择性的抗偏头痛药物。临床数据表明，舒马曲坦能缓解大多数急性偏头痛患者的头痛、恶心和畏光症状，且副作用小、安全性好。非常重要的是，舒马曲坦通过一种新机制发挥作用，我们现在知道双氢麦角胺和其他治疗急性偏头痛的有效化合物也具有这种机制。在本综述中，我们简要回顾了该药物的作用机制以及其使用方面新出现的临床经验。
